Breaking News Instant updates and real-time market news.

MYOK

MyoKardia

$50.25

0.25 (0.50%)

06:34
04/13/18
04/13
06:34
04/13/18
06:34

MyoKardia price target raised to $70 from $56 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised his price target for MyoKardia to $70 following his firm's non deal roadshow with senior management. The analyst came away with greater confidence in the prospects for Phase 3 success in hypertrophic cardiomyopathy. He reiterates an Outperform rating on MyoKardia shares.

MYOK MyoKardia
$50.25

0.25 (0.50%)

03/12/18
COWN
03/12/18
NO CHANGE
Target $73
COWN
Outperform
MyoKardia price target raised to $73 from $56 at Cowen
Cowen analyst Ritu Baral raised her price target on MyoKardia to $73 from $56 following the presentation of its full data from the PIONEER-HCM Phase 2 trial's low-dose cohort B of mavacamten in oHCM patients. The presentation underscored the efficacy data as well as continued clean safety, said Baral, who reiterated her Outperform rating on MyoKardia shares.
03/09/18
FBCO
03/09/18
NO CHANGE
Target $68
FBCO
Outperform
MyoKardia price target raised to $68 from $60 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target on MyoKardia to $68 from $60, saying the company's update on its Phase 2 cohort B data for mavacamten for the treatment of obstructive hypertrophic cardiomyopathy was "just as we hoped." Auster views the news as a "meaningful" de-risking step supporting elevated conviction in the Phase 3 EXLORER study and believes the cohort B results should "incrementally increase" investors' long-term confidence in the mavacamten program. Auster, who has an Outperform rating on shares, added that MyoKardia is one of the most "promising" long-term stories in his coverage.
03/09/18
BMOC
03/09/18
NO CHANGE
Target $83
BMOC
Outperform
MyoKardia price target raised to $83 from $65 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised his price target on MyoKardia to $83, saying the company's Phase 2 PIONEER Cohort-B results "significantly de-risked" EXPLORER Phase 3 trial by establishing a "safe and effective dose titration strategy that could allow physicians to individualize dosing of mavacamten to achieve peak VO2 and LVOT benefit". Somaiya keeps his Outperform rating on MyoKardia, adding that his new price target re-calibrates mavacamten's probability of success.
03/09/18
WEDB
03/09/18
NO CHANGE
Target $69
WEDB
Outperform
MyoKardia price target raised to $69 from $51 at Wedbush
Wedbush analyst David Nierengarten raised his price target on MyoKardia to $69 from $51 after results from the Part B cohort in the company's PIONEER confirmed that a low dose of the investigational agent mavacamten was "effective" at addressing Hypertrophic Cardiomyopathy symptoms, informing on the dosing strategy for the upcoming Phase 3 EXPLORER trial and reducing program risk. In a research note to investors, the analyst, who has an Outperform rating on MyoKardia, noted that a lower dose of mava showed improvement across multiple measures of symptom relief at week 12, with statistical significance achieved in all endpoints except for peak VO2, adding that a 10% improvement in peak VO2 is considered clinically meaningful, and will likely be the goal in EXPLORER at a 24-week timeframe, pending the company's discussions with the U.S. FDA.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$52.12

0.7 (1.36%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Upgrade
Wells Fargo rating change  »

Wells Fargo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

CVS

CVS Health

$74.49

1.33 (1.82%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Conference/Events
Economic Club of Washington, D.C. to hold luncheon meeting »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

WTI

W&T Offshore

$7.38

0.12 (1.65%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Upgrade
W&T Offshore rating change  »

W&T Offshore upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYME

Tyme Technologies

$2.52

-0.11 (-4.18%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Hot Stocks
Tyme Technologies appoints Michele Korfin as CCO »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$35.00

0.87 (2.55%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Conference/Events
Teradata to hold customer conference »

Teradata Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

AMTD

TD Ameritrade

$50.52

0.72 (1.45%)

08:23
10/15/18
10/15
08:23
10/15/18
08:23
Conference/Events
TD Ameritrade to hold a daily program »

TD Ameritrade Network, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IMPV

Imperva

$55.32

0.05 (0.09%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$74.60

0.365 (0.49%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Hot Stocks
Discover reports September charge-off rate 3.2% vs. 3.1% last month »

Reports September 30 or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$188.69

1.55 (0.83%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
10/15/18
10/15
08:20
10/15/18
08:20
General news
NY Empire State index preview: »

NY Empire State index…

XLK

Technology Select Sector SPDR

$70.83

2.15 (3.13%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$36.23

0.53 (1.48%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Conference/Events
Ceridian to hold a conference »

INSIGHTS 2018 will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

XLE

Energy Select Sector SPDR

$72.95

0.2 (0.27%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$108.56

2.05 (1.92%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.78

0.18 (0.34%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$93.18

1.37 (1.49%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$98.33

0.45 (0.46%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Recommendations
Hasbro analyst commentary  »

Hasbro new digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

XLU

Utilities SPDR

$52.97

-0.04 (-0.08%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.38

0.29 (0.56%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$91.07

1.37 (1.53%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GAIN

Gladstone Investment

$10.57

-0.13 (-1.22%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Hot Stocks
Gladstone Investment makes additional investment in portfolio company »

Gladstone Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.